Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | LTC4S | Q16873 | 1/20 | 0.31 |
| ▸ | AHR | P35869 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25844879 | 0.86 | LARS1 (0.33) | MAOBCYP3A4POLB | |
| SCHEMBL25845153 | 0.82 | ALOX5 (0.36) | MAOBALDH1A1CYP3A4POLBLTC4S | |
| SCHEMBL12467259 | 0.82 | ALDH1A1 (0.39) | MAOBALDH1A1CYP3A4SMN1; SMN2POLB | |
| SCHEMBL25844872 | 0.78 | ALDH1A1 (0.36) | ALDH1A1CYP3A4SMN1; SMN2POLB | |
| SCHEMBL5271445 | 0.78 | ALDH1A1 (0.35) | MAOBALDH1A1CYP3A4SMN1; SMN2POLB | |
| SCHEMBL11081166 | 0.77 | AHR (0.47) | MAOBALDH1A1CYP3A4SMN1; SMN2AHR | |
| SCHEMBL25844894 | 0.74 | XDH (0.42) | ALDH1A1CYP3A4SMN1; SMN2 | |
| SCHEMBL25844890 | 0.74 | MAOB (0.34) | MAOBALDH1A1CYP3A4 | |
| SCHEMBL5216895 | 0.73 | AHR (0.35) | MAOBALDH1A1CYP3A4SMN1; SMN2POLB | |
| SCHEMBL12484333 | 0.73 | NPC1 (0.37) | ALDH1A1CYP3A4SMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339919-A1 | BENZO OXYGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICAL APPLICATION THEREOF | AB Pharma Ltd. (CN) | 2023-10-26 | — | — | US | disclosed |
| US-20230339919-A1 | BENZO OXYGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICAL APPLICATION THEREOF | AB Pharma Ltd. (CN) | 2023-10-26 | — | — | US | disclosed |
| EP-4212528-A1 | BENZO OXYGEN-CONTAINING HETEROCYCLIC COMPOUND AND MEDICAL APPLICATION THEREOF | AB Pharma Ltd. (CN) | 2023-07-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339919-A1 | BENZO OXYGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICAL APPLICATION THEREOF | GPR55, GPR65, GPR4 | MAOB 370/4885ALDH1A1 1764/4885CYP3A4 287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.